Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;33(2):518-558.
doi: 10.1038/s41375-018-0255-1. Epub 2018 Sep 12.

CLL Cells Cumulate Genetic Aberrations Prior to the First Therapy Even in Outwardly Inactive Disease Phase

Affiliations
Free PMC article

CLL Cells Cumulate Genetic Aberrations Prior to the First Therapy Even in Outwardly Inactive Disease Phase

María Hernández-Sánchez et al. Leukemia. .
Free PMC article

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Sampling points and follow-ups of the tested cohort. Time-point 1 (TP1) for all tested samples was set to the inactive stage of the disease close to the diagnosis (median from diagnosis to TP1 = 2.1 months). Second time-points (TP2) were all collected prior to CLL-related therapy. Three groups of patients were then characterized based on disease activity in the TP2: (i) Active disease (AD) group - patients with TP2 in disease’s active phase (n = 20, median TTP = 33.9 months, median TTFT = 41.9 months); (ii) Stable disease (SD) group - patients with TP2 in disease’s inactive phase followed by active phase and therapy need (n = 6, median of time to progression (TTP) = 44.7 months, median of time to first treatment (TTFT) = 46.8 months); (iii) Indolent disease (ID) group - patients with TP2 taken in inactive phase, no disease activity or therapy need was reached during follow-up of 3 years (n = 9, median follow-up = 158.1 months). Only one ID case (P31) progressed after 150 months and required therapy intervention
Fig. 2
Fig. 2
List of genes with driver mutations validated using deep targeted sequencing and their changes in variant allele frequency between time-points. Cut-off 5% of VAF was applied for validation of identified mutations. Allele frequency differences were tested across leukemia samples using a Fisher’s exact test. Mutations were considered to be changed if they were significantly different between samples (evolution p-value < 0.05) and their ratio of VAF between TP2 and TP1 was higher than 1.5 (for “increased” mutations) or lower than 0.375 (for “decreased” mutations). Genes with dark blue labels (on the left axis) were CLL drivers previously identified in Puente et al.2 and Landau et al.3 and, where those in light blue were unknown as CLL drivers to date

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013;5:47. doi: 10.1186/gm451. - DOI - PMC - PubMed
    1. Puente XS, Bea S, Valdes-Mas R, Villamor N, Gutierrez-Abril J, Martin-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519–24. doi: 10.1038/nature14666. - DOI - PubMed
    1. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–30. doi: 10.1038/nature15395. - DOI - PMC - PubMed
    1. Ljungstrom V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127:1007–16. doi: 10.1182/blood-2015-10-674572. - DOI - PMC - PubMed
    1. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. doi: 10.1038/ncomms11589. - DOI - PMC - PubMed

Publication types

Substances

Feedback